Ethan Argiris, MD

Argiris A.  Update on chemoradiotherapy for head and neck cancer.  Current Opinions in Oncology. 14:323-9, 2002.

Charles L. Bennett, MD, PhD

Weinberg PD, Hounshell J, Sherman L, Godwin J, Ali S, Tomori C, Bennett CL. Legal, Financial, and public health consequences of HIV-contamination of blood and blood products in the 1980s and 1990s. Annals of Internal Medicine.  136(4):312-319, 2002.

Bennett CL, Crane JM, ASCO Task Force on Quality of Cancer Care.  Quality improvement efforts in oncology: are we ready to begin?  Cancer Investigation.  19(1): 86-95, 2001.

Smith DH, Adams JR, Johnston SRD, Gordon A, Drummond MF, Bennett CL. A Comparative Economic Analysis of Pegylated Liposomal Doxorubicin versus Topotecan in Ovarian Cancer in the United States and United Kingdom. Annals of Oncology, 13:1590-1597, 2002.

Evens AM, Kwaan HC, Kaufman DB, Bennett CL.  TTP/HUS Occurring in a Simultaneous Pancreas/Kidney Transplant Recipient After Clopidogrel Treatment: Evidence of a Nonimmunological Etiology.  Transplantation, 74(6):885-7, 2002.

Bennett CL, Schumock GT, Desai AA, Kwaan HC, Raisch DW, Newlin R, Stadler W. Thalidomide-Associated Deep Vein Thrombosis and Pulmonary Embolism. American Journal of Medicine.  113:603-606, 2002.

Johnson S, Chan J, Bennett CL.  Hepatotoxicity after Prophylaxis with a Nevirapene-Containing Antiretroviral Regimen.  Annals of Internal Medicine, 137(2): 146-147, 2002.

Bennett CL, Raisch DW, Sartor O. Pneumonitis associated with the non-steroidal anti-androgens, bicalutamide, flutamide, and nilutamide: Presumptive evidence of a class effect.  Annals of Internal Medicine.  137(7):625, 2002.

Bennett CL, Price DK, Kim SP, Liu D, Jovanovic BD, Nathan DP, Johnson ME, Montgomery JS, Cude K, Brockbank JC, Sartor O, Figg WD.  Racial Variations in CAG Repeat Lengths Within the Androgen Receptor Gene Among Prostate Cancer Patients of Lower Socioeconomic Status.  Journal of Clinical Oncology, 20(17): 3599-3604, 2002.

Rizzo JD, Lichtin AE, Woolf SH, Seidenfeld J, Bennett CL, Cella D, Djulbegovic B, Goode MJ, Jakubowski AA, Lee SJ, Miller CB, Rarick MU, Regan DH, Browman GP, Gordon MS. Use of epoetin in patients with cancer: evidence-based clinical practice guidelines of the American society of clinical oncology and the American society of hematology.  J Clin Oncol. 2002 Oct 1;20(19):4083-107.

Rizzo JD, Lichtin AE, Woolf SH, Seidenfeld J, Bennett CL, Cella D, Djulbegovic B, Goode MJ, Jakubowski AA, Lee SJ, Miller CB, Rarick MU, Regan DH, Browman GP, Gordon MS.  Use of epoetin in patients with cancer: evidence-based clinical practice guidelines of the American Society of Clinical Oncology and the American Society of Hematology.  Blood. 2002 Oct 1;100(7):2303-20.

Knight SJ, Nathan DP, Siston AK, Kattan MW, Elstein AS, Collela KM, Wolf MS, Slimack NS, Bennett CL, Golub RM.  Pilot Study of Utilities-Based Treatment Decision Intervention for Prostate Cancer Patients.  Clinical Prostate Cancer, 1(2): 105-114, 2002.

Samson DJ, Seidenfeld J, Schmitt B, Hasselblad V, Albertsen PC, Bennett CL.  Systematic Review and Meta-analysis of Monotherapy Compared with Combined Androgen Blockade for Patients with Advanced Prostate Carcinoma.  Cancer, 95(2): 361-76, 2002.

Golub R, Adams J, Dave S, Bennett CL.  Cost-effectiveness considerations in the treatment of essential Thrombocythemia.  Seminars in Oncology, 29(3 suppl 10): 28-32, 2002.

Adams JR, Lyman GH, Djulbegovic B, Feinglass J, Bennett CL.  G-CSF as prophylaxis of febrile Neutropenia in SCLC.  Expert Opinion in Pharmacotherapy, 3(9):1273-81, 2002, September.

Frey P, Stinson T, Siston A, Knight SJ, Ferdman E, Traynor A, O’Gara K, Rademaker A, Bennett CL, Winter JN.  Lack of caregivers limits use of outpaient hematopoietic stem cell transplant program.  Bone Marrow Transplantation, 30:741-748, 2002.

Al B. Benson III, MD

Desch CE, Benson III AB, Smith TJ, et al.  Recommended colorectal cancer surveillance guidelines by the American Society of Clinical Oncology.  J Clin Oncol 6:824-835, 2002.

Harris JE, Ryan L, Hoover Jr. HC, Stuart RK, Oken MM, Benson III AB, et al.  Adjuvant active specific immunotherapy for stage II and III colon cancer with an autologous tumor cell vaccine:  Eastern Cooperative Oncology Group Study E5283.  J Clin Oncol 6:849-859, 2002.

Kemeny MM, Adak S, Gray B, Macdonald JS, Smith T, Lipsitz S, Sigurdson E, O’Dwyer PJ, Benson III, AB.  Combined mortality treatment for resectable metastatic colorectal carcinoma to the liver:  surgical resection of hepatic metastases in combination with continuous infusion of chemotherapy:  an Intergroup Study (ECOG E9288).  J Clin Oncol 20(6):1499-1505, 2002.

Tepper JE, O’Connell M, Niedzwiecki D, Hollis DR, Benson III AB, et al.  Adjuvant therapy in rectal cancer:  analysis of stage, sex, and local control—final report of Intergroup 0114.  J Clin Oncol 20(7):1744-1750, 2002.

Benson III AB, Mitchell E, Abramson N, Klenke B, Ritch P, Burnham JP, McGuirt C, Bonny T, Levin J, Hohneker J.  Oral eniluracil/5-fluorouracil in patients with inoperable hepatocellular carcinoma.  Ann Oncol 13(4):576-581, 2002.

Pasche B, Mulcahy M, Benson III AB.  Molecular markers in prognosis of colorectal cancer and prediction of response to treatment.  Best Pract Res Clin Gastroenterol 16(2):331-345, 2002

Marsh JC, Catalano P, Huang J, Graham DL, Cornfeld MJ, O’Dwyer PJ, Benson III, AB.  Eastern Cooperative Oncology Group phase II trial (E4296) of oral 5-fluorouracil and eniluracil (GW776C85) as a 28-day regimen in metastatic colorectal cancer.  Clin Colorectal Cancer  2(1):43-50, 2002.

Poplin E, Benson III A, Musanti R, Rubin E, Mulcahy.  Pilot study of gemcitabine (10 mg/m2 per min) and cisplatin.  Cancer Chemother Pharmacol 50:80-3, 2002.

McCollum AD, Catalano PJ, Haller DG, Mayer RJ, Macdonald JS, Benson III, AB, Fuchs CS.  Outcomes and toxicity in African-American and Caucasian patients receiving adjuvant chemotherapy for colon cancer:  a secondary analysis of INT-0089.  JNCI 94(15):1160-7, 2002.

Berlin JD, Catalano P, Thomas JP, Kugler JW, Haller DG, Benson III, AB.  Phase III study of gemcitabine in combination with 5-FU vs. gemcitabine alone in patients with advanced pancreatic carcinoma (E2297):  a trial of the Eastern Cooperative Oncology Group. J Clin Oncol 20(15): 3270-75, 2002.

Johnston PG, Rao MS, Catalano P, Allegra C, Hines, Wader S, O’Dwyer PJ, Benson III AB.  Thymidylate synthase expression in primary colorectal cancer:  lack of correlation with outcome and response to 5-FU in metastatic disease sites.  Accepted, J Clin Oncol 2002.

Mulcahy MF and Benson III AB.  New agents for colorectal cancer.  J NCCN 1(1), 2002.

Wadler S, Brain C, Catalano P, Einzig AI, Cella D, Benson AB III.  Randomized phase II trial of either fluorouracil, parenteral hydroxyurea, interferon-alfa-2a and filgrastim or doxorubicin/docetaxel in patients with advanced gastric cancer with quality-of-life assessment:  Eastern Cooperative Oncology Group Study E6296.  Cancer J 8(3):282-286, 2002.

Benson III AB, Mulcahy MF.  Recent and ongoing clinical trials for treating colorectal cancer.  Expert Opin Investig Drugs 11(6):871-880, 2002.

Benson III AB.  Future Directions in Adjuvant Therapy for Rectal Cancer.  Oncology 16(5 Suppl):45-51, 2002.

Wadler, S, Ryan L, Rothenberg, ML, Cleeland C, Cella D, Giguere JK, Stucky-Marshall L, and Benson AB. Randomized trial of standard-dose loperamide, low-dose octreotide acetate, or high-dose octreotide acetate for chemotherapy-induced diarrhea (E1295): An Intergroup Study of the Eastern Cooperative Oncology Group, Advances in Oncology, Eds S W J Lambers & L. Dogliotti, pp227-235, BioScientifica Ltd., Bristol, 2002

Raymond C. Bergan, MD

Liu Y, Jovanovic B, Pins M, Lee C, Bergan RC.  Over expression of endoglin in human prostate cancer suppresses cell detachment, migration and invasion.  Oncogene.  21:8272-8281, 2002.

Bergan RC.  Cancer chemoprevention.  The Journal 8:4-12, 2002.

Lisa N. Boggio, MD

Kwaan HC, Wang J, Boggio L.  Abnormalities in hemostasis in acute promyelocytic leukemia.  Hematology Oncology.  20(1): 33-41, 2002.

Westerman MP, Green D, Gilman-Sachs A, Beamen K, Freels S, Boggio L, Allen S, Schlegel R, Williamson P.  Clotting activity in sickle cell trait.  American Journal of Hematology.  69: 89-94, 2002.

James F. Brandman, MD

Paice, J, Brandman, JF et al. “Pain and Suffering in an Adolescent with Neuroblastoma” Cancer Practice, 10(Supp. 1:S4-S8, 2002.

Elizabeth Eklund, MD

Semel, AC, Seales, EC, Singhal, A, Eklund, EA, Colley, KJ, Bellis, SL.  Hyposialylation of integrins stimulates the activity of myeloid fibronectin receptors.  (2002) J. Biol. Chem in press.

Eklund, EA, Goldenberg, I, Lu, Y, Andrejic, J, Kakar, R.  SHP1 protein tyrosine phosphatase regulates HoxA10 DNA-binding and transcriptional repression activity in undifferentiated myeloid cells. (2002) J. Biol. Chem 39:36878-36888 (corresponding author)

Ronald Gartenhaus, MD

Gartenhaus, RB, Prachand S., Paniaqua, M. Li, Y., Gordon L.I.: Arsenic Trioxide Cytotoxicity in Steroid and Chemotherapy-Resistant Myeloma Cell lines: Enhancement of Apoptosis by Manipulation of Cellular Redox State  Clin. Can. Res., Feb;8(2): 566-72. 2002.

Ross Johnston MD, Kenneth W. Altman MD, PhD, and Gartenhaus RB: Chronic Lymphocytic Leukemia Manifesting in the Paranasal Sinuses. Otolaryngol Head Neck Surg. Dec;127(6):582-4, 2002.

Shi B, Levenson V, Gartenhaus RB:  Identification and characterization of a novel enhancer for the human MCT-1 oncogene promoter.  J Cellular Biochem (in press), 2002.

Leo I. Gordon, MD

Gartenhaus RB, Prachand S, Paniaqua M, Li Y, Gordon LI.  Arsenic trioxide cytotoxicity in steroid and chemotherapy-resistant myeloma cell lines:  enhancement of apoptosis by manipulation of cellular redox state.  Clin Cancer Res  8:566-572, 2002.

Gordon LI, Witzig TE, Wiseman GA, Flinn IW, Stewart SS, Silverman DH, Emmanouilides C, Cripe L, Saleh M, Czuczman MS, Olejnik T, White CA, Grillo-Lopez AJ.  Yttrium 90 Ibritumomab tiuxetan radioimmunotherapy for relapsed or refractory low-grade non-Hodgkin’s lymphoma.  Sem in Onc  29(1):87-92, 2002.

Mehta J, Singhal, Gordon LI, Tallman M, Williams S, Luyun R, Ali MY, Oyama Y, Villa M, Shook T, Winter J. Peripheral stem cells. Cobe spectra is superior to Fenwal CS 3000 Plus for collection of hematopoietic stem cells.  Bone Marrow Transplantation 29:563-567, 2002.

Witzig TE, Gordon LI, Cabanillas F, Czuczman MS, Emmanouilides C, Joyce R, Pohlman BL, Bartlett NL, Wiseman GA, Padre N, Grillo-Lopez AJ, Multani P, White CA.  Randomized controlled trial of Yttrium-90-labeled ibritumomab tiuxetan radioimmunotherapy versus rituximab immunotherapy for patients with relapsed or refractory low-grade, follicular, or transformed B-cell non-Hodgkin’s lymphoma.  J Clin Oncol 20(10):2453-2463, 2002.

Wiseman GA, Gordon LI, Multani PS, Witzig TE, Spies S, Bartlett NL, Schilder RJ, Murray JL, Saleh M, Allen RS, Grillo-Lopez AJ, White CA.  Ibritumomab tiuxetan radioimmunotherapy for patients with relapsed or refractory non-Hodgkin’s Lymphoma and mild thrombocytopenia:  a phase II multicenter trial.  Blood 99(12):4336-4342, 2002.

Witzig TE, Flinn IW, Gordon LI, Emmanouilides C, Czuczman MS, Saleh MN, Cripe L, Wiseman G, Olejnik T, Multani PS, White CA.  Treatment with ibritumomab tiuxetan radioimmunotherapy in patients with rituximab-refractory follicular non-Hodgkin’s lymphoma.  J Clin Oncol 20(15):3262-3269, 2002.

Xiaoping S, Gordon LI, Peterson LC.  Transformation of follicular lymphoma to acute lymphoblastic leukemia.  Arch Pathol Lab Med 126:997-998, August 2002.

Tomblyn, M, Gordon LI, Singhal S, Tallman M. Williams S, Winter J, Mehta. J.  Rarity of toxigenic Clostridium difficile infections after hematopoietic stem cell transplantation:  implications for symptomatic management of diarrhea.  Bone Marrow Transplantation 30:517-519, 2002.

Evens AM, Gordon LI.  Burkitt’s and Burkitt-like Lymphoma.  Curr Treat Options Oncol.  Aug: 3(4):291-305, 2002.

William J. Gradishar, MD

Gradishar WJ, Hellmund R.  A rationale for the reinitiation of adjuvant tamoxifen therapy in women receiving fewer than 5 years of therapy.  Clin Breast Cancer 2:282-286, 2002.

Antman K, Abraido-Lanza AF, Blum D, Brownfield E, Cicatelli B, Debor MD, Emmons K, Fitzgibbon M, Gapstur SM, Gradishar W, et al.  Reducing disparities in breast cancer survival:  a Columbia University and Avon Breast Cancer Research and Care Network Symposium.  Breast Cancer Res Treat 75:269-280, 2002.

Gradishar WJ, Morrow M.  Advances in endocrine therapy of metastatic breast cancer.  Br J Surg 89:1489-1492, 2002.

Miller KD, Gradishar W, Schuchter L, Sparano J, Cobleigh M, Robert N, Rasmussen H, Sledge GW.  A randomized phase II pilot trial of adjuvant marimastat in patients with early stage breast cancer.  Ann Oncol 13:1220-1224, 2002.

Osborne CK, Gradishar WJ, Forbes JF, Ravdin PM.  Choosing between endocrine therapy and chemotherapy – or is there a role for combination therapy?  Breast Cancer Res Treat 75(Suppl 1):S37-S44, 2002.

Gradishar WJ.  Docetaxel and capecitabine in breast cancer:  current status and future directions.  Cancer Conference Highlights 6:3-5, 2002.

Morrow M, Gradishar W.  Recent advances in breast cancer.  Br Med J 2:282-286, 2002.

David Green, MD, PhD

Billote DB, Glisson SN, Green D, Wixson RL. A prospective, randomized study of preoperative autologous donation for hip replacement surgery. J Bone Joint Surg 84A:1299-1304. 2002.

Westerman MP, Green D, Gilman-Sachs A, Beaman K, Freels S, Boggio L, Allen S, Schlegel R, Williamson P.  Coagulation changes in individuals with sickle cell trait.  Am J Hem 69:89-94, 2002.

Reding MT, Lei S, Lei H, Green D, Gill J, Conti-Fine BM. Distribution of Th1- and Th2-induced anti- factor VIII IgG subclasses in congenital and acquired hemophilia patients. Thromb Haemost 88:568-75, 2002.

Green D. Pitfalls in the use of anticoagulants. Hemodial Int 6:47-53, 2002.

Timothy M. Kuzel, MD

Kuzel TM, Kies M, Wu N, Hsieh Y, Rademaker AW.  Phase I trial of oral estramustine and 3-hour infusional paclitaxel for the treatment of hormone-refractory prostate cancer.  Cancer Investigation 20(5 and 6):634-643, 2002.

Hinton S, Catalano P, Einhorn LH, Loehrer PJ, Kuzel TM, Vaughn D, Wilding G.  Phase II study of Paclitaxel plus Gemcitabine in refractory germ cell tumors (E9897):  a trial of the ECOG.  J Clin Oncol 20:1864-1873, 2002.

Duvic M, Kuzel TM, Olsen E, et al.  Quality of life improvements in cutaneous T-cell lymphoma patients treated with DAB389IL-2 fusion protein (Ontak).  Clinical Lymphoma 2(4):222-228, 2002.

Breneman D, Duvic M, Kuzel T, Yocum R, Truglia J, and Stevens V.  Phase I-II Trial of Bexarotene Gel for the skin-directed Treatment of Patients with Cutaneous T-cell Lymphoma. Archives of Derm  138(3):325-332, 2002.

Clark JI, Kuzel TM, Lestingi TM, Fisher SG, Sorokin P, Martone B, Viola M, and Sosman JA.  A multi-institutional phase II trial of a novel inpatient schedule of continuous interleukin-2 with interferon alpha-2b in advanced renal cell carcinoma. Annals of Oncol 13: 606-613, 2002.

Guitart J, Wickless SC, Oyama Y, Kuzel TM, Rosen ST, Traynor A, Burt R.  Long-term remission after allogeneic hematopoietic stem cell transplantation for refractory cutaneous T cell lymphoma. Arch Dermatol 138:1359-1365, 2002.

Frankel AE, Rossi P, Kuzel T, Foss F.  Diphtheria fusion protein therapy of chemoresistant malignancies.  Current Cancer Drug Targets 2:19-36, 2002.

Hau C. Kwaan, MD, PhD

Kwaan HC,  Wang J,  Boggio LN.  Abnormalities in hemostasis in acute promyelocytic leukemia.  Hematol Oncol 20:33-41, 2002.

Bennett CL, Schumock GT, Desai AA, Kwaan HC, Raisch DW, Newlin R, Stadler W. Thalidomide – associated deep vein thrombosis and pulmonary embolism.  Amer J Med 113: 603-606, 2002.

Evens AM, Kwaan HC, Kaufman DB, Bennett CL.  TTP/HUS occurring in simultaneous pancreas/kidney transplant recipient after clopidogrel treatment evidence of a nonimmunological etiology.  Transplantation  73:1-3, 2002.

Jayesh Mehta, MD

Powles R, Sirohi B, Kulkarni S, Treleaven J, Rudin C, Sankpal S, Goyal S, Horton C, Millar B, Saso R, Singhal S, Mehta J. Collection of peripheral blood stem cells in newly diagnosed myeloma patients without any prior cytoreductive therapy: the first step towards an ‘operational cure’? Bone Marrow Transplant 30:479-484, 2002.

Singhal S, Powles R, Henslee-Downey PJ, Chiang KY, Treleaven J, Godder K, Kulkarni S, van Rhee F, Sirohi B, Pinkerton CR, Meller S, Mehta J. Allogeneic transplantation from HLA-matched sibling or partially HLA-mismatched related donors for primary 2002refractory acute leukemia. Bone Marrow Transplant 29:291-295, 2002.

Mehta J, Singhal S. Chronic graft-versus-host disease after allogeneic peripheral-blood stem-cell transplantation: a little methotrexate goes a long way. J Clin Oncol 20:603-604 2002.

Mehta J, Powles R, Sirohi B, Treleaven J, Kulkarni S, Saso R, Tait D, Singhal S. Does donor-recipient ABO-incompatibility protect against relapse after allogeneic bone marrow transplantation in first remission acute myeloid leukemia? Bone Marrow Transplant 29:853-859, 2002.

Mehta J, Singhal S, Gordon L, Tallman M, Williams S, Luyun R, Ali MY, Oyama Y, Villa M, Shook T, Winter J. Cobe Spectra is superior to Fenwal CS 3000 Plus for collection of hematopoietic stem cells. Bone Marrow Transplant 29:563-567, 2002.

Singhal S, Powles R, Sirohi B, Treleaven J, Kulkarni S, Mehta J. Response to induction chemotherapy is not essential to obtain survival benefit from high-dose melphalan and autotransplantation in myeloma. Bone Marrow Transplant 30:673-679, 2002.

Ali MY, Oyama Y, Monreal J, Winter J, Tallman M, Gordon LI, Williams S, Singhal S, Mehta J. Reassessing the definition of myeloid engraftment after autotransplantation: it is not necessary to see 0.5 x 109/L neutrophils on 3 consecutive days to define myeloid recovery. Bone Marrow Transplant 30:749-752, 2002.

Tomblyn M, Gordon L, Singhal S, Tallman M, Williams S, Winter J, Mehta J. Rarity of toxigenic Clostridium difficile infections after hematopoietic stem cell transplantation: implications for symptomatic management of diarrhea. Bone Marrow Transplant 30:517-519, 2002.

Kulkarni S, Powles R, Sirohi B, Treleaven J, Horton C, Atra A, Rudin C, Goyal S, Sankpal S, Meller S, Pinkerton CR, Mehta J, Singhal S. Thalidomide after allogeneic hematopoietic stem cell transplantation: Activity in chronic but not in acute graft-versus-host disease. Bone Marrow Transplant (Accepted for publication).

Powles R, Sirohi B, Treleaven J, Kulkarni S, Tait D, Singhal S, Mehta J. The role of post-transplant maintenance chemotherapy in improving the outcome of autotransplantation in adult acute lymphoblastic leukemia. Blood 100:1641-1647, 2002.

Mehta J, Powles R, Sirohi B, Treleaven J, Swansbury GJ, Kulkarni S, Saso R, Singhal S. Impact of cytogenetics on the outcome of autotransplantation for acute myeloid leukemia in first remission: is the benefit of intensive pre-transplant therapy limited to patients with good karyotypes? Bone Marrow Transplant (Accepted for publication).

Ali MY, Oyama Y, Monreal J, Winter JN, Tallman MS, Williams SF, Singhal S, Gordon LI, Mehta J. Ideal or actual body weight to calculate CD34+ cell doses for autologous hematopoietic stem cell transplantation? Bone Marrow Transplant (Accepted for publication).

Mehta J. ABO incompatibility and relapse risk in patients undergoing allogeneic marrow transplantation for acute myeloid leukemia. Bone Marrow Transplant 30:547-548, 2002.

Senior Residents Karin Ulstrup and Courtney Noble at the VA Ambulatory Clinic 2004 Spring Luncheon

Mehta J., Singhal S.  Authorship limits. N Engl J Med 347:1118, 2002.

Mary F. Mulcahy, MD

Chen F, Kamradt M, Mulcahy M, Byun Y, Xu H, McKay MJ, Cryns VL.  Caspase Proteolysis of the Cohesin Componant RAD21 Promotes Apoptosis.  Journal of Biological Chemistry, 277(19):16775-81, May 10, 2002. 

Pasch B, Mulcahy M, Benson AB III.  Molecular Markers in Prognosis of Colorectal Cancer and Prediction of Response to Treatment.  Best Practice and Research.  Clinical Gastroenterology, 16:331-45, April 2002.

Mulcahy MF and Benson AB III.  Posttreatment Surveillance of Colon and Rectal Cancers.  ASCO Educational Book, 38th annual meeting: 646-651, May 2002.

Mulcahy MF and Benson AB III.  Recent and Ongoing Clinical Trials for Treating Colorectal Cancer.  Expert Opinion on Investigational Drugs,11(6), 2002.

Poplin E, Benson AB III, Musati R, Rubin E, Mulcahy MF.  Pilot Study of Gemcitabine (10 mg/m2/min) and Cisplatin.  Journal of Cancer Chemotherapy and Pharmacology, 50 (1):80-3, July 2002.

Hidayatullah G. Munshi, MD

Munshi HG, Ghosh S, Wu YI, Sen R, Green KJ, Stack MS. Proteinase suppression by E-cadherin mediated cell-cell attachment in premalignant oral keratinocytes. J Biol Chem 277:38159-67, 2002.

Munshi HG, Wu YI, Ariztia E, Stack MS.  Calcium regulation of matrix metalloproteinase 2-mediated migration in oral squamous carcinoma cells. J Biol Chem 277:41480-8, 2002.

Ghosh S, Munshi HG, Sen R, Linz-McGillem LA, Goldman RD, Lorch J, Green KJ, Jones JCR, Stack MS.  Loss of Adhesion-regulated proteinase production is correlated with invasive activity in oral squamous cell carcinoma. Cancer 95:2524-33, 2002.

Munshi HG, Merajver SD, Valdez R, Baker LH, Cooney KA.  Metastatic dedifferentiated chordoma with elevated beta-hCG:  a case report.  Am J Clin Oncol 25:274-276, 2002.

Munshi HG, Stack MS.  Analysis of matrix degradation.  Methods Cell Biol 69:195-205, 2002.

Ruth M. O’Regan, MD

Dardes RC, O’Regan RM, Gajdos C, Robinson SP, Bentrem D De Los Reyes A, Jordan VC.  Effects of a new clinically relevant antiestrogen (GW5638) related to tamoxifen on breast and endometrial cancer growth in vivo.  Clin Cancer Res 6;1995-2001, 2002.

O’Regan RM, Jordan VC.  The evolution of tamoxifen therapy in breast cancer: selective estrogen receptor modulators and down-regulators.  Lancet Oncology 3;207-14, 2002.

O’Regan RM, Gajdos C, Dardes RC, De los Reyes A, Park WC, Jordan VC.  Effects of raloxifene after tamoxifen on breast and endometrial cancer growth.  J Natl Cancer Inst 20;274-83, 2002.

Judith A. Paice, PhD, RN, FAAN

Tanabe P, Ferket K, Thomas R, Paice J, and Marcantonio R: The effect of standard care, ibuprofen, and distraction on pain relief and patient satisfaction in children with musculoskeletal pain. Journal of Emergency Nursing , 28(2):118-125, 2002.

Paice JA, Brandman J, Cappleman J, Wirpsa MJ: Multidisciplinary rounds: pain and suffering in a child with neuroblastoma. Cancer Practice  10: S4-S8, 2002.

Paice JA: Understanding nociceptive pain. Nursing 2002 32 (3):74-75, 2002.

Paice JA: Mechanisms and management of neuropathic pain. New Taipei Journal of Medicine 4:67-72, 2002.

Hanks-Bell M, Paice JA: Versed on acute care units. Clinical Journal of Oncology Nursing 6:367-369, 2002.

Paice JA: Managing psychological conditions in palliative care.  American Journal of Nursing 102 (11):36-43, 2002.

Gordon DB, Pellino TA, Miaskowski C, McNeill JA, Paice JA, LaFerriere D, Bookbinder M:  A 10 year review of quality improvement monitoring in pain management:  recommendations for standardized outcome measurement.  Pain Management NursingI 3:116-130, 2002.

Boris Pasche, MD, PhD

Pasche, B, Mulcahy, M, Benson, AB   Molecular markers in prognosis of colorectal cancer and prediction of response to treatment.  Best Practice & Research Clinical Gastroenterology 16:331-345, 2002.

Leonidas C. Platanias, MD, PhD

Verma, A., Stock, W., Norohna, S., Shah, R., Bradlow,  B., and Platanias, L.C.  Progressive Transformation of germinal centers: report of 2 cases and review of literature.  Acta Haematol 108:33-8, 2002.

Verma, A., and Platanias, L.C.  Signaling via the interferon-α receptor in chronic myelogenous leukemia cells.  Leuk. Lymphoma 43:703-9, 2001.

Deonarain,R., Platanias, L.C., and  Fish, E.N.  Interferon α/β receptor interactions; A complex story unfolding.  Curr. Pharm. Des  8:2131-7, 2002.

Verma, A., Deb, D.K., Sassano, A., Uddin, S., Varga, J., Wickrema, A., and Platanias, L.C.  Activation of the p38 Mitogen activated protein kinase mediates the suppressive effects of Type I interferons and transforming growth factor-β on normal hematopoiesis.  J. Biol. Chem  277:7726-7735, 2002.

Mahmud, D.L., Amlak, M, Deb, D.K., Platanias, L.C., Uddin, S., and Wickrema, A.  Phosphorylation of forkhead transcription factors by Erythropoietin and stem cell factor prevent their interaction with co-activator p300 and acetylation in erythroid progenitor cells.  Oncogene 21:1556-1562, 2002.

Uddin, S., Sassano, A., Verma, A., Deb, D.K., Majchrzak, B., Rahman, A., Malik, A.B., Fish, E.N., and Platanias, L.C.  Protein kinase C delta (PKC-d) is activated by Type I interferons and mediates phosphorylation of Stat1 on serine 727.  J. Biol. Chem 277, 1408-1416, 2002.

Lekmine, F., Sassano, A., Uddin, S., Majchrzak, B., Miura, O., Druker, B.J., Fish, E.N., Imamoto, A., and Platanias, L.C.  The CrkL adapter protein is required for Type I Interferon-dependent gene transcription and activation of the Small G-protein Rap1.  Bioch. Biophys. Res. Comm 291, 744-750, 2002.

Platanias, L.C.  Role of the p38 Map kinase pathway in interferon signaling.  Pharm. Ther (In press).

Verma, A., Deb, D.K., Sassano, A., Kambhampati, S., Wickrema, A., Uddin, S., Mohindru, M., Van Besien, K., and Platanias, L.C.  Cutting edge: Activation of the p38 mitogen-activated protein kinase signaling pathway mediates cytokine-induced hematopoietic suppression in aplastic anemia.  J. Immunol  15; 168:5984-8, 2002.

Roy, S.K., Hu, J., Meng, Q., Xia, Y., Shapiro, P.S., Reddy, S.P., Platanias, L.C., Lindner, D.J., Johnson, P.F., Pritchard, C., Pages, G., Pouyssegur, J., and Kalvakolanu, D.V.  MEKK1 plays a critical role in activating the transcription factor C/EBP-beta-dependent gene expression in response to IFN-gamma.  Proc. Natl Acad Sci USA  11:7945-50, 2002.

Verma, A., Stock, W., Lait, M., Ferrer, K., Quinn, J., Platanias, L.C.  Actiomycosis presenting as an oral ulcer in a neutropenic patient.  South Med J  95:1105, 2002.

Verma, A., Mohindru, M., Deb, D.K., Sassano, A., Kambhampati, S., Ravandi, F., Minucci, S., Kalvakolanu, D.V., Platanias, L.C.  Activation of Rac1 and the p38 mitogen-activated protein kinase pathway in response to arsenic trioxide.  J. Biol. Chem 277:44988-95, 2002.

Steven T. Rosen, MD

Dai Y, Dalton W, Landowski T, Rosen ST, Dent P, Grant S.  Combined Treatment with the Checkpoint Abrogator UCN-01 and MEK1/2 Inhibitors Potently Induces Apoptosis in Drug-Sensitive and Resistant Myeloma Cells Through an IL-6 Independent Mechanism.  Blood, 100:(9)3333-3343, 2002.

Nabhan C, Gajria D, Krett NL, Gandhi V, Rosen ST.  Caspase activation is required for Gemcitabine Activity in Multiple Myeloma Cell Lines.  Molecular Cancer Therapeutics, 1:1221-1227, 2002.

Greenstein S, Krett NL, Kurosawa Y, Ma C, Chauhan D, Hideshima T, Anderson KC, Rosen ST. Characterizations Of The MM.1 Human Multiple Myeloma (MM) Cell Lines: A Model System To Elucidate The Characteristics, Behavior, and Signaling Of Steroid-sensitive And Resistant MM Cells.  Experimental Hematology, In Press.

Guitart J, Wickless, SC, Oyama Y, Kuzel TM, Rosen ST, Traynor A, Burt R.  Long Term Remission Following Allogeneic Hematopoietic Stem Cell Transplantation for Refractory Cutaneous T Cell Lymphoma.  Archives of Dermatolog, 2002, In Press.

Wu JJ, Guitart J, Tucker R, Kuzel TM, Rosen ST.  Primary Cutaneous Anaplastic Large Cell Lymphoma Treated with Liposomal Doxorubicin (Doxil®) Leading to Complete Remission.  Archives of Dermatology, 2002, In Press.

Seema Singhal, MD

Powles R, Sirohi B, Kulkarni S, Treleaven J, Rudin C, Sankpal S, Goyal S, Horton C, Millar B, Saso R, Singhal S, Mehta J. Collection of peripheral blood stem cells in newly diagnosed myeloma patients without any prior cytoreductive therapy: the first step towards an ‘operational cure’? Bone Marrow Transplant  30:479-484, 2002.

Singhal S, Powles R, Henslee-Downey PJ, Chiang KY, Treleaven J, Godder K, Kulkarni S, van Rhee F, Sirohi B, Pinkerton CR, Meller S, Mehta J. Allogeneic transplantation from HLA-matched sibling or partially HLA-mismatched related donors for primary refractory acute leukemia. Bone Marrow Transplant 29:291-295, 2002.

Mehta J, Singhal S. Chronic graft-versus-host disease after allogeneic peripheral-blood stem-cell transplantation: a little methotrexate goes a long way. J Clin Oncol 20:603-604, 2002.

Mehta J, Powles R, Sirohi B, Treleaven J, Kulkarni S, Saso R, Tait D, Singhal S. Does donor-recipient ABO-incompatibility protect against relapse after allogeneic bone marrow transplantation in first remission acute myeloid leukemia? Bone Marrow Transplant 29:853-859, 2002.

Mehta J, Singhal S, Gordon L, Tallman M, Williams S, Luyun R, Ali MY, Oyama Y, Villa M, Shook T, Winter J. Cobe Spectra is superior to Fenwal CS 3000 Plus for collection of hematopoietic stem cells. Bone Marrow Transplant  29:563-567, 2002.

Singhal S, Powles R, Sirohi B, Treleaven J, Kulkarni S, Mehta J. Response to induction chemotherapy is not essential to obtain survival benefit from high-dose melphalan and autotransplantation in myeloma. Bone Marrow Transplant 30:673-679, 2002.

Ali MY, Oyama Y, Monreal J, Winter J, Tallman M, Gordon LI, Williams S, Singhal S, Mehta J. Reassessing the definition of myeloid engraftment after autotransplantation: it is not necessary to see 0.5 x 109/L neutrophils on 3 consecutive days to define myeloid recovery. Bone Marrow Transplant 30:749-752, 2002.

Tomblyn M, Gordon L, Singhal S, Tallman M, Williams S, Winter J, Mehta J. Rarity of toxigenic Clostridium difficile infections after hematopoietic stem cell transplantation: implications for symptomatic management of diarrhea. Bone Marrow Transplant  30:517-519, 2002.

Kulkarni S, Powles R, Sirohi B, Treleaven J, Horton C, Atra A, Rudin C, Goyal S, Sankpal S, Meller S, Pinkerton CR, Mehta J, Singhal S. Thalidomide after allogeneic hematopoietic stem cell transplantation: Activity in chronic but not in acute graft-versus-host disease. Bone Marrow Transplant (Accepted for publication).

Powles R, Sirohi B, Treleaven J, Kulkarni S, Tait D, Singhal S, Mehta J. The role of post-transplant maintenance chemotherapy in improving the outcome of autotransplantation in adult acute lymphoblastic leukemia. Blood  100:1641-1647, 2002.

Mehta J, Powles R, Sirohi B, Treleaven J, Swansbury GJ, Kulkarni S, Saso R, Singhal S. Impact of cytogenetics on the outcome of autotransplantation for acute myeloid leukemia in first remission: is the benefit of intensive pre-transplant therapy limited to patients with good karyotypes? Bone Marrow Transplant (Accepted for publication).

Ali MY, Oyama Y, Monreal J, Winter JN, Tallman MS, Williams SF, Singhal S, Gordon LI, Mehta J. Ideal or actual body weight to calculate CD34+ cell doses for autologous hematopoietic stem cell transplantation? Bone Marrow Transplant (Accepted for publication).

Gerald A. Soff, MD

Sellak H, Yang X, Cao X, Cornwell T, Soff GA, and Lincoln T.  Zinc finger transcription factor Sp1 as a molecular target for nitric oxide-and cyclic nucleotide-mediated suppression of cGMP-dependent protein kinase-Ia  expression in vascular smooth muscle cells.  Circulation Research 90:405-412, 2002.

Martin S. Tallman, MD

Kantarjian H, Sawyers CL, Hochhaus A, Guilhot F, Schiffer C, Niederweiser D, Gambacorti-Passerini C, Stone R, Goldman J, Fischer T, Reiffers J, Miller C, Tallman MS, O’Brien S, Brown R, Silver R, Gratwohl A, Loughran T, Mandelli F, Saglio G, Ottmann O, Lazzarino M, Tura S, Baccarani M, Thiery F, Morra M, Russell N, Zoellner U, Resta D, Capdeville R, Talpaz M, Druker B.  Hematologic and cytogenetic responses to imatinib mesylate in chronic myeloid leukemia.  N Engl J Med  46:645-52, 2002.

Douglas VK, Tallman MS, Cripe LD, Peterson LC.  Morphologic changes included by thrombopoietin in acute myeloid leukemia.  Am J Clin Path 117:844-50, 2002.

Lal A, Slivnick D, Tallman MS, Peterson L.  Hairy cell leukemia presenting as localized skeletal involvement.  Leuk Lymph 43:2207-2211,2002.

Nabhan C, Peterson LA, Kent SA, Tallman, MS, Dewald G, Multani P, Gordon LI.  Secondary acute myeloid leukemia with MLL gene management following radioimmunotherapy (RAIT) for non-Hodgkin’s lymphoma. Leukemia Lymphoma 43:245-9, 2002.

Tallman MS, Andersen JW, Schiffer CA, Appelbaum FR, Feusner JH, Ogden A, Shepherd L, Willman C, Bloomfield CD, Rowe JM, Wiernik PH. All-trans retinoic acid in acute promyelocytic leukemia:  long-term outcome and prognostic factor analysis from the North American Intergroup Protocol.  Blood 100:4298-4302, 2002.

Ali MY, Oyama Y, Monreal J, Tallman MS, et al. Reassessing the definition of myeloid engraftment after autotransplantation: it is not necessary to see 0.5 x 109/L neutrophils on 3 consecutive days to define myeloid recovery. Bone Marrow Transplantation, 30: 749-52, 2002.

Tomblyn M, Gordon L, Singhal S, Tallman MS, Williams S, Winter J, Mehta J. Rarity of toxigenic clostridium difficile infections after hematopoietic stem cell transplantation: implications for symptomatic management of diarrhea.  Bone Marrow Transplant 30:517-519, 2002.

Mehta J, Singhal S, Gordon L, Tallman M, Williams S, Luyun R, Ali MY, Oyama Y, Villa M, Shook T, Winter J.  Cobe Spectra is superior to Tenwal C33000 plus for collection of hematopoietic stem cells.  Bone Marrow Transplantation 29:563-567, 2002.

Weiss MA, Aliff TB, Tallman MS, Frankel SR, Kalaycio ME, Maslak PG, Jurcic JG, Scheinberg DA, Roma TE.  A single high-dose of idarubicin combined with cytarabine as induction therapy for adult patients with recurrent or refractory acute lymphoblastic leukemia.  Cancer 95:581-7, 2002.

Jamie H. Von Roenn, MD

Von Roenn JH.  Pharmacologic interventions for cancer-related weight loss.  Oncology Issues 17:18-21, 2002.

Krown SE, Li P, Von Roenn JH, Paredes J, Huang J, Testa MA.  Efficacy of low-dose interferon with antiretroviral therapy in Kaposi’s sarcoma:  a randomized phase II AIDS Clinical Trials Group study.  J Interferon and Cytokine Res 22:295-303, 2002.

Krown SE, Von Roenn JH, Paredes J, et al.  Randomized, open-label phase II multicenter trial of two doses of interferon alpha-2B combined with didanosine in patients with AIDS-associated Kaposi’s sarcoma: AIDS Clinical Trials Group Protocol 206.  Cytokine Res 22:295-303, 2002.

Evans SR, Krown SE, Testa MA, Cooley TP, Von Roenn JH.  A phase II evaluation of low-dose oral etoposide for the treatment of relapsed or progressive AIDS-related Kaposi’s sarcoma:  an AIDS Clinical Trials Group clinical study.  J Clin Oncol 20:3236-3241, 2002.

Miles SA, Dezube BJ, Lee JY, Krown SE, Fletcher MA, Saville MW, Kaplan L, Groopman J, Scadden DT, Cooley T, Von Roenn J, Friedman-Kien A.  Antitumor activity of oral 9-cis retinoic acid in HIV-associated Kaposi’s sarcoma.  J AIDS 16:421-429, 2002.

Von Roenn JH, Scheinberg D, Loehrer PJ Sr.  Role of symptom control and palliative care abstract presentations.  J Clin Oncol 20:880-882, 2002.

Sigmund A. Weitzman, MD

Kamp DW, Panduri V, Weitzman SA, Chandel N. Asbestos-induced alveolar epithelial cell apoptosis: role of mitochondrial dysfunction caused by iron-derived free radicals. Mol Cell Biochem; 234/235:153-60. 2002.

Jane N. Winter, MD

Tomblyn M, Gordon L, Singhal S, Tallman M, Williams S, Winter J, Mehta J.   Rarity of toxigenic Clostridium difficile infections after hematopoietic stem cell transplantation:  implications for symptomatic management of diarrhea.  Bone Marrow Transplant 30:517-519, 2002.

Frey P, Stinson T, Siston A, Knight SJ, Ferdman E, Traynor A, O’Gara K, Rademaker A, Benett C, Winter JN.  Lack of caregivers limits use of outpatient hematopoetic stem cell transplant program.  Bone Marrow